PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?

Dokumenttyp:: Journal Article; Editorial Material
Autor(en):: Lehmann-Horn, Klaus; Penkert, Horst; Grein, Peter; Leppmeier, Ulrich; Teuber-Hanselmann, Sarah; Hemmer, Bernhard; Berthele, Achim
Titel:: PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?
Abstract:: Progressive multifocal leukoencephalopathy (PML), which is caused by the John Cunningham virus (JCV), is a rare brain disease that results in persistent neurologic disability or death. In multiple sclerosis (MS), PML is a major concern in patients treated with natalizumab, and treatment duration (more than 2 years), preceding immunosuppression, and JCV antibody serostatus are identified risk factors, which are used for risk stratification, patient monitoring, and counseling.
Zeitschriftentitel:: Neurology
Jahr:: 2016
Band / Volume:: 87
Heft / Issue:: 4
Seitenangaben Beitrag:: 440-1
Sprache:: eng
Volltext / DOI:: doi:10.1212/WNL.0000000000002900
PubMed:: http://view.ncbi.nlm.nih.gov/pubmed/27343070
Print-ISSN:: 0028-3878
TUM Einrichtung:: Neurologische Klinik und Poliklinik
BibTeX

Vorkommen: